source
- Xenon shares plunge 23% after voluntary hold on psychiatry trials, despite filing NDA for epilepsy drugXenon Pharmaceuticals announced that its lead asset azetukalner (AZK) has been submitted to the FDA as a new drug application for focal onset seizures. At the same time, the company disclosed a vo…
- Roche opens new research center in Boston, expanding its local presenceRoche announced the opening of a new research facility in Boston, adding to its existing operations in the city. The center will focus on early-stage drug discovery and will house several hundred…